Overview

Study of Nolasiban to Increase Pregnancy Rates in Women Undergoing IVF

Status:
Completed
Trial end date:
2020-11-11
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to confirm the efficacy of a single oral 900 mg dose of nolasiban versus placebo to increase the ongoing clinical pregnancy rate at 10 weeks post-embryo transfer (ET) day.
Phase:
Phase 3
Details
Lead Sponsor:
ObsEva SA